Oricell Therapeutics has closed a $110 million pre-IPO funding round to expand its footprint and accelerate a GPC3-targeted autologous CAR-T program for liver cancer toward registrational trials. The company expects its lead candidate, Ori-C101, to advance based on prior investigator-initiated work and a registrational phase 1 trial. The funding round was co-led by Vivo Capital, Beijing Medical and Health Care Industry Investment Fund, and Qiming Venture Partners, among others. Oricell is positioning Ori-C101 against a difficult solid-tumor target by using an armored approach intended to help engineered cells function in immunosuppressive tumor microenvironments. Company updates also reference additional pipeline candidates, including OriCAR-017 in a Phase 1/2 study in China for multiple myeloma. The raise signals continued investor appetite for solid-tumor CAR-T development despite historically high execution risk in this space.